pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-16-2 |
Genomic Coordinates | chr3: 160404745 - 160404825 |
Description | Homo sapiens miR-16-2 stem-loop |
Comment | This entry represents a second putative hairpin precursor sequence for miR-16, located on chromosome 3 (see also MIR:MI0000070). The sequence was previously named mir-16-3 here and in references . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-16-2-3p | ||||||||||||||||||
Sequence | 53| CCAAUAUUACUGUGCUGCUUUA |74 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ATP6V1C1 | ||||||||||||||||||||
Synonyms | ATP6C, ATP6D, VATC, Vma5 | ||||||||||||||||||||
Description | ATPase H+ transporting V1 subunit C1 | ||||||||||||||||||||
Transcript | NM_001695 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ATP6V1C1 | |||||||||||||||||||||
3'UTR of ATP6V1C1 (miRNA target sites are highlighted) |
>ATP6V1C1|NM_001695|3'UTR 1 AAATGGGCTCCTCCCCCGACAATCCTGTCCTTGTGTTTGTGTGTGCTAACAGAAATAAGTTGCAGTATGGTCGTACTTTT 81 AACTCTAGTATCCTTTGCTTGCTTCTTACGCCCTTTCCTAGGTGAATTCTCCCACAGTGGTCTGTATCTCAACATTTTCT 161 TTTTAAAGGAAAAAATATATATATATAGTTTCTTTTTATTGATCAGGTCTGTAAATGTGTACTAAAAAAATCAGAGTTTA 241 TTTATAAACAAAATAGTTTATTTAAAGAGAAGGTCTCTTCCTTATTGATATCATGGTATGCATTAATTCCATTTGTTACT 321 ATTGTGCACAAAAGCCCTGTTCACAGGGGAATGGTGTAAACATTTATACTGTTTTGTTCACTGTATTTAGTAGACATAAC 401 TGTTGAATAGTTACTGAATCATGATGTAAAGAATATGTGACCATCTTCAGGTATGGGATTTCTGAACGTTTCAAATTTCA 481 ATCAATGAGCACTGTCAACACCCACAGGAGAGAATAAAATTACCTGTGCAAAGGTGTATTGTGGTGTGTGTAACTTAAGA 561 TTACAGTTCTGTTTGAGAGTTAAATGATGTCATAGCTCACTTGCTATGCTGCTTCCAGGATTTTGTTATATGCTGAGGTG 641 TAACCATTTGTGTTGTCTGACTTTCGTATGATTTAATTGAGCCAAATTTGGGTCAGAACACAAATTTGAAGATGACTTTT 721 CAGTATATGATGGGTATTTACATTTGAACACTAGAATTTTAGGTCTCTCAAATAATTAAGAATAGAGCCAGTTTTGAATA 801 AAGTCTAGCAGAACTATGCAGCTTTAGTCATTTGTTTTGTCTAAGTCTGTATTTTATGTGTTGTCTTCTTAAGATCTATA 881 ATTTTGGCATTTATGTCATTTGTGACATAGTCTGAAAATAGAGACATTGTTGGCCTTTAAAATCTCAGAAATGAATGACT 961 TAATTTAGTGTCCTGAAAGAGCTTTTAAAAGAGGATTTTGTGGCAATGTTTCTCTTACTACGTACTCACAGGTTTGCAAA 1041 TGGGAAAAAAGTTTACATTTCAGTTTAGGGGCATATCTAAGCTATGCTATTCCCTTTAGAAAATTAGCCTCCAAAATCTT 1121 TTGTTTCAAAATATTATATTATTTCATAAATAATTTCAAGCAAATACAGACATCCACAATGTAGAACATGAGAGACCCCC 1201 TCCCTCAATTTCCACCTCCCAAGGGAAGTTTATGTATTTTTCTAGGCCCTTTTCTATGTCTTTACATCTCTGTCTCACAC 1281 ACACACACGTATACACACACACAGTTTATTTTTAATAAAATAGGATTATACCACACACATCCTGTCACTTGCTTTTTTGC 1361 TTAAGAGTATATCTAAGAGAATCCTTTGTGTCAGTGAAGCTGGAGCTACCTCATTCTTTTAACTGGCTGCGTGGCGTTCC 1441 ATTGAGTGTCTGTCATCATGTGTTTAGCCGAGTGGATGGATAGTCTGCTTGTTTTTAGTTTTTGCTCTTAACAAACACTG 1521 CTGCAGTCAGCATCCTTGCACAGATTTCTTTGTATACTTGTATTAGTATTTCTGTAAGATCTGAGAAGTGGAATTTGTAG 1601 GGTCATAGGTTATGTACACTTAAGTTTTTGACACTCACTGCCAAGTCATCTGTCAGAATTCTAAACTAAAGACATGTTTG 1681 GAGTGTGGATTTATCTTCAGTTTTTCTTTGGACAAGAGGAAGCTGTGAAAGATTTTGCTATCAGAAAATTTTGGTTCTTT 1761 GTCTTTTGCACATGTTCTTTGAGTCTTAGTATCTGTAACGTGGCGCTACTCTCTCTATCATGGGGGGGCATGTTTTGACA 1841 TTAAATTGACTTTTAAGAAAAACATGTCACTAACCTGAAGCTCAGCCACACAGTGACTTTTAAGGTTTTATTTAGACTTT 1921 ACTGTTGTTCTCATGAGAGTAGGTACAGACTGCATAAGGTTTAGAATCCCAGCATATGTCTGAAACGACGGGACTTTCAC 2001 TGTGATTTCCACCAGAGAAATTATAGCAGAGTGGCTGAGCATGTGCTCTGAGGCCAGGCCCCAGCTCTGCTGCTGACGAG 2081 CTGTGTGGTCCTGGGCAGAGTGGTCTCCGAGTTCCAGTCCCTCCTCTGTAAAATGGGCATGATTAGAGTGCCCACCGCAT 2161 TAGGGATGTTGGGGTGAGTCAGTGTGACCCCACGTGCACAGAAAGTGCTGCGAGTGGTGCATGGTGAGAGGTTGATGCAG 2241 GTACTTAGCCCTTGGGGAACACAGGTAGTTCCTTTTCACTGTGTTTAATTTGGGAAAATCCAGATCCACATCATTGTAGA 2321 GTCTGAGGGTTAGAAGGAAGTCATTGTGTCTAACATAACAACAGAGCAGTTTGTGTCACTGAGCTCCAGTCTGTGCTGGA 2401 TTATTGATATTGTTGGTGGCGGTCACCATTCCTGGAAAGGGACTGTCCCAAGCCACTTACCTTCCCGAGGAGTCTGCTGG 2481 TTCTCCTTGAGGATAGTGCTTAGATAACAGACTCATTAAACATTTACTGAGTGTCTGTCAGGGATCATTCACATCCACAT 2561 CATCCTCCCGGCCCCTCCCCGTGTTGTTCATGGAGGGAGTACTGGCGGTCCCCATTTTCATGTATGGAGACTTCAGGTGA 2641 AAGAAGTTAAGTGAATTCTTTGTTGAGTCACAAATCTTGAGCCAGTCAGAATTTGAACCTAAGATTTTTGACTGCTGGTT 2721 GTCACACTTCCCGCCCCACACTCAACTGTTGTGTGAATGAGCCAGACACATTGCTTAACCTGAGTCCGAGATGGACAATG 2801 GTATAGGAAAGATATTCGGTATGGAGAATCAGATGTTAACTTGTGTTGCTATTTTTGTTTTGTTTTGTTTTGTTTTGTTT 2881 TTGAGACAAGGTCTTGCTCTGTCACCCAGGCTAGAGTGCAGTGGCATGATCAGGGCTTACTGCAGCCTCACCCTCGATTT 2961 CCTGGGCTCAAGCAATCCTCCCACCTCAGCCCCCAAGTAGCTGGGCCTACAGGTGCGTGCTACCACGCCTGGCCAATTTT 3041 TTAAATTTTAGCACAGATGAGGTCTCACTATGTTGCCCGGGCTGGTCTCGAACTCCTGAGCTCAAGGGATCCTCCCGCCT 3121 CAGCCTCCCAAAGTGCTGGTGTTACAGGCATAAGCCACCACGCCTGGCCTGTGTTGCTATTATATTTGGCAGGAACCCAG 3201 AGTCCAGAACATTTCATCTATGATGGGTTAGATAATGTGTCTAGTTGTTTGCATGCCAATTTCAGTAGCCTCAGTTATTC 3281 AACCTAGGAGATTTTTCTACCTCTTTACTACCCTGCTGAAGTTGCTCTTCAGCAGAAAATCTTTGTGGAACACATTCCAC 3361 ACTTTGAAATCTTCGTGGAACAAAAGATATTTGTGGAACCAATCTTTGTGGAACATATTCCAGCTTTTTGAATGAGTGCA 3441 TATCCAGTAGTACCTTTAAAGTAACACTTTGTACATAACAAATACTCAGCAAATGTGAAACTTTATTTGCTCTTACTTCA 3521 AAATTAGTCCAAAATGTTGGAAATAAAATATAAGACATTGATCTAGATATGAGGTTTTTCTCCTTCATTCTCAGCTGTCG 3601 AAGAAATCAAAGTAGCATATGCACAAGGTTAAAAACCACATATACAAATACTATAGAACAGCTTATAATGAAAACCTTGC 3681 CTGCCTTTATAAAAAATGTGATTATCTTCTTCTGTTAATGTCAATAAAAGATGGTTTGTCCTAGAAGGTCTATAAATGGT 3761 ATTATGTTCTGGAGGAAACCTAGCAAAAACTTTGCTAGTTTAGTACTTGTCTCTAAATTGATGTTCACCCATTTCAATAT 3841 TGCACTTATTAATGGTCTTTATTTTTCTAGCATAGATAACAATTGATTCTTTAGATTCATATATGGAGGTAATTCTTGCT 3921 TTCTAAAGAAAGGAATATGGCACATTGGAACCATTTTATTCACCAGTGGATTTACCCTTAGAGTATTTTTAGATCTGAGC 4001 TGATGACTTGTGAGAGAAAAAGGGAACAGAGTAAAGCCATGGAAGCCATGAACAGTAAGAGACTGCCGCCTGGCATGGTT 4081 TCTTCTTCTGCAGAAGATGAAACTGAGGAGAAACAAGACAACATCCTTCATACCAGGAATGGTCAAGATAATGCAAGAAG 4161 AAAAAAGCTTTCAAACAAATCAGAAGGCAGTCAACAAACAGAAAGGGGGACATTCCTTCCCTGGCAGTTACTCAAAACTG 4241 AAATTGCTTATTGTGTACACCGGGGCTTGTACTTGGGGAATTTAATAAAAATGCTCATTACCAAGCTCCA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 528.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | hESCs (WA-09) |
Disease | 528.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
CLIP-seq Support 1 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000395862.3 | 3UTR | UUCACCCAUUUCAAUAUUGCACUUAUUAAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000395862.3 | 3UTR | UUCACCCAUUUCAAUAUUGCACUUAUUAAUGGU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
75 hsa-miR-16-2-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004488 | RARB | retinoic acid receptor beta | 3 | 1 | ||||||||
MIRT038707 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 1 | 1 | ||||||||
MIRT057208 | PPIF | peptidylprolyl isomerase F | 2 | 4 | ||||||||
MIRT058726 | RSBN1 | round spermatid basic protein 1 | 2 | 8 | ||||||||
MIRT074502 | NFATC2IP | nuclear factor of activated T-cells 2 interacting protein | 2 | 4 | ||||||||
MIRT081544 | ZNF431 | zinc finger protein 431 | 2 | 4 | ||||||||
MIRT096893 | ERBB2IP | erbb2 interacting protein | 2 | 2 | ||||||||
MIRT105124 | MYC | MYC proto-oncogene, bHLH transcription factor | 2 | 2 | ||||||||
MIRT107898 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 | 2 | 4 | ||||||||
MIRT109432 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT166742 | PAPD7 | poly(A) RNA polymerase D7, non-canonical | 2 | 6 | ||||||||
MIRT171257 | YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma | 2 | 2 | ||||||||
MIRT192760 | B2M | beta-2-microglobulin | 2 | 2 | ||||||||
MIRT194905 | RBBP6 | RB binding protein 6, ubiquitin ligase | 2 | 8 | ||||||||
MIRT215599 | SUB1 | SUB1 homolog, transcriptional regulator | 2 | 2 | ||||||||
MIRT223632 | ATP6V1C1 | ATPase H+ transporting V1 subunit C1 | 2 | 4 | ||||||||
MIRT241605 | AMOTL1 | angiomotin like 1 | 2 | 4 | ||||||||
MIRT291174 | SH3GLB1 | SH3 domain containing GRB2 like, endophilin B1 | 2 | 2 | ||||||||
MIRT444286 | ABCG2 | ATP binding cassette subfamily G member 2 (Junior blood group) | 2 | 2 | ||||||||
MIRT463285 | ZFX | zinc finger protein, X-linked | 2 | 4 | ||||||||
MIRT471759 | NUS1 | NUS1 dehydrodolichyl diphosphate synthase subunit | 2 | 8 | ||||||||
MIRT479611 | CDC25A | cell division cycle 25A | 2 | 2 | ||||||||
MIRT481497 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 2 | 8 | ||||||||
MIRT483117 | SH3BP5 | SH3 domain binding protein 5 | 2 | 2 | ||||||||
MIRT502279 | GRPEL2 | GrpE like 2, mitochondrial | 2 | 8 | ||||||||
MIRT507838 | CCNT1 | cyclin T1 | 2 | 2 | ||||||||
MIRT508179 | MTRNR2L6 | MT-RNR2-like 6 | 2 | 4 | ||||||||
MIRT510576 | UBE2D3 | ubiquitin conjugating enzyme E2 D3 | 2 | 6 | ||||||||
MIRT517853 | RPS4X | ribosomal protein S4, X-linked | 2 | 4 | ||||||||
MIRT521690 | PRKAA1 | protein kinase AMP-activated catalytic subunit alpha 1 | 2 | 8 | ||||||||
MIRT525070 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT527082 | UBE2E3 | ubiquitin conjugating enzyme E2 E3 | 2 | 2 | ||||||||
MIRT529552 | EI24 | EI24, autophagy associated transmembrane protein | 2 | 2 | ||||||||
MIRT530426 | SULT1B1 | sulfotransferase family 1B member 1 | 2 | 2 | ||||||||
MIRT533909 | TBC1D15 | TBC1 domain family member 15 | 2 | 2 | ||||||||
MIRT536627 | IPO7 | importin 7 | 2 | 2 | ||||||||
MIRT537647 | ERGIC2 | ERGIC and golgi 2 | 2 | 4 | ||||||||
MIRT538512 | CLCN3 | chloride voltage-gated channel 3 | 2 | 2 | ||||||||
MIRT539219 | ANP32E | acidic nuclear phosphoprotein 32 family member E | 2 | 6 | ||||||||
MIRT539348 | AGO2 | argonaute 2, RISC catalytic component | 2 | 4 | ||||||||
MIRT539954 | CCT4 | chaperonin containing TCP1 subunit 4 | 2 | 2 | ||||||||
MIRT541208 | HOXA10 | homeobox A10 | 2 | 2 | ||||||||
MIRT543216 | TMEM117 | transmembrane protein 117 | 2 | 2 | ||||||||
MIRT543399 | DROSHA | drosha ribonuclease III | 2 | 2 | ||||||||
MIRT546648 | RPS6KA5 | ribosomal protein S6 kinase A5 | 2 | 2 | ||||||||
MIRT546852 | RAB1A | RAB1A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT549917 | MRPS30 | mitochondrial ribosomal protein S30 | 2 | 2 | ||||||||
MIRT552998 | USP46 | ubiquitin specific peptidase 46 | 2 | 2 | ||||||||
MIRT555254 | PREPL | prolyl endopeptidase-like | 2 | 2 | ||||||||
MIRT555956 | NRIP1 | nuclear receptor interacting protein 1 | 2 | 2 | ||||||||
MIRT557095 | HOXA9 | homeobox A9 | 2 | 2 | ||||||||
MIRT561396 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT561654 | RNF219 | ring finger protein 219 | 2 | 2 | ||||||||
MIRT563101 | PABPC4L | poly(A) binding protein cytoplasmic 4 like | 2 | 2 | ||||||||
MIRT565979 | RNF44 | ring finger protein 44 | 2 | 2 | ||||||||
MIRT572396 | CCDC14 | coiled-coil domain containing 14 | 2 | 2 | ||||||||
MIRT574400 | TM9SF3 | transmembrane 9 superfamily member 3 | 2 | 2 | ||||||||
MIRT607623 | VSNL1 | visinin like 1 | 2 | 2 | ||||||||
MIRT610645 | CTGF | connective tissue growth factor | 2 | 2 | ||||||||
MIRT623379 | LPP | LIM domain containing preferred translocation partner in lipoma | 2 | 2 | ||||||||
MIRT624687 | AR | androgen receptor | 2 | 2 | ||||||||
MIRT632089 | ALDH1A2 | aldehyde dehydrogenase 1 family member A2 | 2 | 2 | ||||||||
MIRT644216 | CBS | cystathionine-beta-synthase | 2 | 2 | ||||||||
MIRT647841 | BID | BH3 interacting domain death agonist | 2 | 2 | ||||||||
MIRT651649 | WASF2 | WAS protein family member 2 | 2 | 2 | ||||||||
MIRT689064 | AGMAT | agmatinase | 2 | 2 | ||||||||
MIRT698150 | TNPO1 | transportin 1 | 2 | 2 | ||||||||
MIRT700516 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | 2 | 2 | ||||||||
MIRT704081 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | 2 | 2 | ||||||||
MIRT705970 | ACBD5 | acyl-CoA binding domain containing 5 | 2 | 2 | ||||||||
MIRT715694 | COMMD3-BMI1 | COMMD3-BMI1 readthrough | 2 | 2 | ||||||||
MIRT717184 | BMI1 | BMI1 proto-oncogene, polycomb ring finger | 2 | 2 | ||||||||
MIRT724607 | AP3B1 | adaptor related protein complex 3 beta 1 subunit | 2 | 2 | ||||||||
MIRT724854 | IGFBP5 | insulin like growth factor binding protein 5 | 2 | 2 | ||||||||
MIRT725401 | LRIG2 | leucine rich repeats and immunoglobulin like domains 2 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|